Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income	$ 42,824	$ 90,915	$ 10,787
Adjustments to reconcile net income to cash provided by (used in) operating activities:
Gain on sale of discontinued operations	0	(64,600)	0
Goodwill impairment	0	0	14,510
Deferred income tax provision, net	2,380	491	1,166
Provision for bad debts on accounts receivable	1,553	825	546
Depreciation and amortization	9,849	10,058	9,846
Stock-based compensation	5,819	3,028	2,570
Pension and post-retirement benefit plans expense	1,846	1,424	3,237
Amortization of deferred financing costs	122	105	90
Excess tax benefit attributable to stock-based compensation	(551)	0	(110)
Loss on deferred compensation plan investments, net	77	446	304
Gain from Company-owned life insurance proceeds	0	(849)	0
Contingent consideration liability remeasurement	321	0	0
Other	186	(152)	257
Decrease (increase) in operating assets
Trade receivables, net	4,223	(40,339)	(28,071)
Income tax refund receivable	2,785	4,409	(5,970)
Prepaid expenses and other current assets	1,110	530	(3,170)
Other assets, net	(298)	(27)	(57)
Increase (decrease) in operating liabilities
Accounts payable and other current liabilities	1,788	5,653	(12,471)
Accrued payroll costs	(5,503)	(248)	7,422
Income taxes payable	(1,657)	(34,934)	(504)
Other long-term liabilities	3,306	(2,317)	83
Cash provided by (used in) operating activities	70,180	(25,582)	465
Cash flows from investing activities:
Capital expenditures	(8,328)	(6,011)	(8,145)
Acquisition, net of cash received	0	(2,611)	0
Proceeds from disposition of business	0	117,887	0
Proceeds from the disposition of assets held within the Rabbi Trust	445	2,668	3,278
Purchase of assets held within the Rabbi Trust	(481)	(2,436)	(3,697)
Proceeds from Company-owned life insurance	0	1,037	0
Other	0	1	17
Cash (used in) provided by investing activities	(8,364)	110,535	(8,547)
Cash flows from financing activities:
Proceeds from bank line of credit	604,668	684,427	591,688
Payments on bank line of credit	(617,529)	(653,701)	(550,081)
Proceeds from financing agreement	2,914	0	0
Payments of capital expenditure financing	(1,274)	(1,280)	(1,452)
Payments of loan financing costs	0	(460)	0
Short-term vendor financing	(252)	(160)	(180)
Proceeds from exercise of stock options, net of shares tendered in payment of exercise	381	1,131	598
Excess tax benefit attributable to stock-based compensation	551	0	110
Repurchases of common stock	(38,471)	(101,771)	(29,810)
Cash dividend	(12,545)	(12,776)	(3,297)
Cash (used in) provided by financing activities	(61,557)	(84,590)	7,576
Change in cash and cash equivalents	259	363	(506)
Cash and cash equivalents at beginning of period	1,238	875	1,381
Cash and cash equivalents at end of period	$ 1,497	$ 1,238	$ 875